Financial StabilityCash runway is expected to fund operations into the second half of 2027, providing financial stability for ongoing projects.
Platform PotentialThe strategic shift towards leveraging their platform for siRNA therapeutics in autoimmune diseases is seen as a move in the right direction, focusing on differentiated technology.
Technology DevelopmentNew milestone data confirm successful siRNA delivery to T cells in non-human primates, with potent knockdown of B2M, LAT1, and VAV1 without inducing T cell activation.